Skandinaviska Enskilda Banken AB publ raised its position in shares of Danaher Corporation (NYSE:DHR) by 4.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 110,837 shares of the conglomerate’s stock after buying an additional 4,500 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in Danaher were worth $9,508,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. ETRADE Capital Management LLC raised its position in shares of Danaher by 5.1% in the 2nd quarter. ETRADE Capital Management LLC now owns 19,075 shares of the conglomerate’s stock worth $1,610,000 after purchasing an additional 917 shares during the last quarter. Honeywell International Inc. purchased a new position in shares of Danaher in the 2nd quarter worth about $25,317,000. Roundview Capital LLC raised its position in shares of Danaher by 2.0% in the 2nd quarter. Roundview Capital LLC now owns 25,674 shares of the conglomerate’s stock worth $2,167,000 after purchasing an additional 502 shares during the last quarter. Eastern Bank raised its position in shares of Danaher by 4,291.1% in the 2nd quarter. Eastern Bank now owns 128,001 shares of the conglomerate’s stock worth $10,802,000 after purchasing an additional 125,086 shares during the last quarter. Finally, Perkins Coie Trust Co raised its position in shares of Danaher by 2.0% in the 2nd quarter. Perkins Coie Trust Co now owns 29,431 shares of the conglomerate’s stock worth $2,484,000 after purchasing an additional 586 shares during the last quarter. 76.32% of the stock is owned by institutional investors and hedge funds.

DHR has been the subject of several recent analyst reports. Zacks Investment Research raised Danaher from a “hold” rating to a “buy” rating and set a $97.00 price target for the company in a research report on Thursday, October 5th. Cowen reaffirmed a “buy” rating and issued a $90.00 price target on shares of Danaher in a research report on Wednesday, October 4th. Goldman Sachs Group reaffirmed a “neutral” rating and issued a $83.00 price target on shares of Danaher in a research report on Tuesday, September 26th. Robert W. Baird lifted their price objective on Danaher from $87.00 to $97.00 and gave the stock an “outperform” rating in a report on Friday, October 20th. Finally, Credit Suisse Group lifted their price objective on Danaher from $93.00 to $96.00 and gave the stock an “outperform” rating in a report on Friday, October 20th. One research analyst has rated the stock with a sell rating, four have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $93.31.

In other Danaher news, CAO Robert S. Lutz sold 11,189 shares of the business’s stock in a transaction dated Monday, October 23rd. The stock was sold at an average price of $91.66, for a total transaction of $1,025,583.74. Following the completion of the sale, the chief accounting officer now directly owns 18,314 shares in the company, valued at approximately $1,678,661.24. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Thomas Patrick Joyce, Jr. sold 125,989 shares of the business’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $92.64, for a total value of $11,671,620.96. Following the sale, the chief executive officer now owns 271,737 shares of the company’s stock, valued at $25,173,715.68. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 273,810 shares of company stock valued at $25,218,813. Corporate insiders own 12.20% of the company’s stock.

Shares of Danaher Corporation (NYSE DHR) opened at $92.74 on Wednesday. Danaher Corporation has a twelve month low of $76.27 and a twelve month high of $94.82. The company has a market capitalization of $64,566.07, a PE ratio of 23.86, a P/E/G ratio of 2.21 and a beta of 1.02. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.00.

Danaher (NYSE:DHR) last released its quarterly earnings data on Thursday, October 19th. The conglomerate reported $1.00 EPS for the quarter, topping the consensus estimate of $0.95 by $0.05. Danaher had a return on equity of 11.29% and a net margin of 13.36%. The company had revenue of $4.53 billion during the quarter, compared to the consensus estimate of $4.47 billion. During the same period last year, the company earned $0.87 EPS. Danaher’s revenue for the quarter was up 9.6% on a year-over-year basis. analysts predict that Danaher Corporation will post 3.99 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, January 26th. Shareholders of record on Friday, December 29th will be paid a dividend of $0.14 per share. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.60%. Danaher’s dividend payout ratio is currently 16.52%.

ILLEGAL ACTIVITY NOTICE: “Skandinaviska Enskilda Banken AB publ Purchases 4,500 Shares of Danaher Corporation (DHR)” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://www.thecerbatgem.com/2017/12/06/skandinaviska-enskilda-banken-ab-publ-purchases-4500-shares-of-danaher-corporation-dhr.html.

Danaher Company Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Stock Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related stocks with our FREE daily email newsletter.